Work

Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors

Year: 2012

Type: review

Abstract: Anti-angiogenic therapies, including bevacizumab, are being used with increasing frequency in the management of malignant glioma. Common clinically significant toxicities include hypertension and proteinuria, poor wound healing, and the potential for thromboembolic events. Literature related to the use of bevacizumab in malignant glioma, reported toxicities in this patient population, and management of these toxicities was reviewed. Recommendations for assessment and management are provided. Anti-angiogenic therapies will continue to have a role in the treatment of malignant glioma. Further studies of the prevention, assessment, and management of these toxicities are warranted.

Source: Neuro-Oncology

DOI: 10.1093/neuonc/nor223

Authors: T. S. Armstrong, P. Y. Wen, M. R. Gilbert, D. Schiff

Institutions: Brigham and Women's Hospital, The University of Texas MD Anderson Cancer Center, University of Tennessee Health Science Center, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, University of Virginia

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2152089491

FWCI: 1.142

Cites: 85

Cited by: 63

Related to: 10